Peptides DB
Research-centric peptide and protocol reference hub

Teriparatide (PTH 1-34) record · updated 9h ago

Healing & recoveryGrade A · human clinicalResearch use only
All 20 studiesJump to the evidenceCompare
What is Teriparatide (PTH 1-34) used for?

Teriparatide, a synthetic form of parathyroid hormone (PTH 1-34), is primarily used in the treatment of osteoporosis. It acts as an anabolic agent, stimulating bone formation through its mechanism of action, which involves binding to specific PTH receptors on osteoblasts, leading to increased osteoblast proliferation and activity. This results in enhanced bone mineral density and strength, making it particularly beneficial for postmenopausal women at high risk of fractures.

How it works: PTH1 receptor agonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where Teriparatide (PTH 1-34) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 157 registered trials. It describes the research record, not a recommendation.

Identity
NameTeriparatide (PTH 1-34)
Chain length—
Molecular weight4,118 Da
FormulaC181H291N55O51S2
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 16133850. No verified residue count for this compound.

Pharmacology
MechanismPTH1 receptor agonist
RouteSubcutaneous injection
Half-life~1 hour
Time to peak30 min
Duration24 months
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Nov 1, 2026. How this works →
Research stats
Total studies20
Human / animal / cellular12 / 7 / 0
Highest trial phasePhase 3
Years covered2023–2026
Latest study5d ago
Publication history
20232026
Research funding
295 NIH projects · $19.8M awarded · through FY2027
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

20 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Real-World Effectiveness of Osteoporosis Treatments on Bone Strength and the Impact of Sequential Anabolic Therapy
Finding39.5% increase in vertebral strength with Romo at 12 months, n=57, 95% CI [34.2, 44.7]
Human2026Full text read0.80
Bioengineered acellular tissue engineered vessels versus autogenous fistulae for haemodialysis access: a multicentre, randomised, controlled, phase 3 trial.
FindingGlobal relative patency of 1·17 (95% CI 1·04-1·31, p=0·0090).
Human2026Full text read0.90
Ascorbic acid mitigates oxidative structural degradation in bovine spermatozoa: a label-free quantitative phase microscopy study.
FindingNot reported in abstract.
Animal2026Full text read0.70
Encapsulated L-Lysine: from physicochemical properties to broiler responses.
FindingMelting enthalpy reduced from 107.9 to 83.37 J/g.
Animal2026Full text read0.80
Asymmetrical blending of Tenebrio molitor and Hermetia illucens meals in broiler nutrition: a novel strategy.
FindingHigher body weight gain in TM4-HI2 compared to Control, P<0.05.
Animal2026Full text read0.80
Molecular detection of African horse sickness virus from selected areas in Ethiopia.
Finding21.88% of samples tested positive for African horse sickness virus.
Animal2026Full text read0.80
Ovarian follicular dynamics and pregnancy outcomes of Thai swamp buffaloes (Bubalus bubalis) submitted to ovulation-synchronization protocol with different timing of insemination.
Finding71.4% pregnancy rate at 72 hours post P4-device removal.
Animal2026Full text read0.80
Comparison of ultrasound-guided two-point block of the rhomboid intercostal vs. thoracic paravertebral for postoperative analgesia in patients undergoing three-port thoracoscopic surgery: a prospective, randomized, non-inferiority study.
FindingMean difference in resting NRS scores at 24 h was 0.088 (95% CI, -0.377 to 0.553).
Human2026Full text read0.80
Transitions between contraceptive states among women aged 15-49 Years in Guinea.
Finding61.1% probability of transitioning following pregnancy outcomes.
Human2026Full text read0.80
Osteoporosis limits neurological recovery after spinal cord injury through PDGF-BB-MMP14 signaling
FindingNot reported in abstract.
Human2026Full text read0.70
Impact of Preoperative Teriparatide Use on Proximal Junctional Kyphosis Prevention in Osteopenic/Osteoporotic Patients Undergoing Adult Spinal Deformity Surgery: A Propensity Score-Matched Study
Finding44.2% PJK incidence in teriparatide group vs. 52.5% in non-teriparatide group, P = 0.426
Human2026Full text read0.80
Fragmented prevention in rural South Africa: a qualitative study of Biokineticists' perspectives on health system barriers to early detection of non-communicable diseases.
FindingNot reported in abstract.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Teriparatide (PTH 1-34) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Teriparatide (PTH 1-34) is discussed should be drawn from it.